Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Aerie Pharmace (AERI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aerie Pharmace's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Aerie Pharmace historical data, for real-time data please try another search
15.25 +0.00    +0.00%
18/11 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 15.24 / 15.25
  • Day's Range: 15.24 - 15.25
Aerie Pharmace 15.25 +0.00 +0.00%

Aerie Pharmace Company Profile

 
Get an in-depth profile of Aerie Pharmace, including a general overview of the company's business and key management, as well as employee data and location and contact information.
Industry
Sector
Employees

376

Equity Type

ORD

. As of November 21, 2022, Aerie Pharmaceuticals, Inc. was acquired by Alcon Research, Ltd. Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina

Contact Information

Address 4301 Emperor Boulevard Suite 400
Durham, 27703
United States
Phone 919 237 5300
Fax -
Web
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AERI Comments

Write your thoughts about Aerie Pharmace
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherif Mohsen
Sherif Mohsen Aug 23, 2022 2:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sidus Space Signs MOU with Exo-Space to Support Edge Computing Technology
Alessandro Boccaletti
Alessandro Boccaletti May 25, 2017 3:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2017/06/16 P.
Joel Westerstrom
Joel Westerstrom Feb 20, 2015 12:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hi All,. . I got a recommendation from a good friend of mine over here in Europe to buy Aerie since, according to him, they will completely transform the management of glaucoma. Normally I tend not to trust good friends when they give me advice on how to invest, but this time I made an exception since he is an opthamologist specialising in glaucoma. Sadly the stock has dropped since I bought it, though the strong dollar still leaves me with a profit when converted to my local currency. I reckon the main reason for the decline is the sell-off from the venture funds - or do you have another plausible explanation? The news coming from the company seem to have been good and the potential should be huge given the seriousness of the condition targeted and the lack of good drugs today.. . Best,. . Sven
Joel Westerstrom
Joel Westerstrom Feb 20, 2015 12:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email